745 related articles for article (PubMed ID: 25156247)
1. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
2. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice.
Stroeve JH; Brufau G; Stellaard F; Gonzalez FJ; Staels B; Kuipers F
Lab Invest; 2010 Oct; 90(10):1457-67. PubMed ID: 20531290
[TBL] [Abstract][Full Text] [Related]
3. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
[TBL] [Abstract][Full Text] [Related]
4. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
[TBL] [Abstract][Full Text] [Related]
5. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
[TBL] [Abstract][Full Text] [Related]
6. An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training.
Côté I; Ngo Sock ET; Lévy É; Lavoie JM
Eur J Nutr; 2013 Aug; 52(5):1523-32. PubMed ID: 23117815
[TBL] [Abstract][Full Text] [Related]
7. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L
Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887
[TBL] [Abstract][Full Text] [Related]
8. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.
Byun S; Jung H; Chen J; Kim YC; Kim DH; Kong B; Guo G; Kemper B; Kemper JK
J Biol Chem; 2019 May; 294(22):8732-8744. PubMed ID: 30996006
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol-lowering effects of taurine through the reduction of ileal FXR signaling due to the alteration of ileal bile acid composition.
Miyata M; Tanaka T; Takahashi K; Funaki A; Sugiura Y
Amino Acids; 2021 Oct; 53(10):1523-1532. PubMed ID: 34596761
[TBL] [Abstract][Full Text] [Related]
11. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency.
Huang M; Kong B; Zhang M; Rizzolo D; Armstrong LE; Schumacher JD; Chow MD; Lee YH; Joseph LB; Stofan M; Zhang L; Guo GL
Lab Invest; 2020 Sep; 100(9):1158-1168. PubMed ID: 32404932
[TBL] [Abstract][Full Text] [Related]
12. Astragaloside IV ameliorates diet-induced hepatic steatosis in obese mice by inhibiting intestinal FXR via intestinal flora remodeling.
Zhai Y; Zhou W; Yan X; Qiao Y; Guan L; Zhang Z; Liu H; Jiang J; Liu J; Peng L
Phytomedicine; 2022 Dec; 107():154444. PubMed ID: 36155217
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.
Zhang Z; Du Z; Liu Q; Wu T; Tang Q; Zhang J; Huang C; Huang Y; Li R; Li Y; Zhao Y; Zhang G; Zhou J; Huang H; Fang Z; He J
Metabolism; 2021 May; 118():154728. PubMed ID: 33581130
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel function of hepatic long-chain acyl-CoA synthetase-1 (ACSL1) in bile acid synthesis and its regulation by bile acid-activated farnesoid X receptor.
Singh AB; Dong B; Xu Y; Zhang Y; Liu J
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Mar; 1864(3):358-371. PubMed ID: 30580099
[TBL] [Abstract][Full Text] [Related]
16. Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice.
de Boer JF; Schonewille M; Boesjes M; Wolters H; Bloks VW; Bos T; van Dijk TH; Jurdzinski A; Boverhof R; Wolters JC; Kuivenhoven JA; van Deursen JM; Oude Elferink RPJ; Moschetta A; Kremoser C; Verkade HJ; Kuipers F; Groen AK
Gastroenterology; 2017 Apr; 152(5):1126-1138.e6. PubMed ID: 28065787
[TBL] [Abstract][Full Text] [Related]
17. Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation.
Rau M; Stieger B; Monte MJ; Schmitt J; Jahn D; Frey-Wagner I; Raselli T; Marin JJ; Müllhaupt B; Rogler G; Geier A
Inflamm Bowel Dis; 2016 Oct; 22(10):2382-9. PubMed ID: 27580383
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine.
Kim I; Ahn SH; Inagaki T; Choi M; Ito S; Guo GL; Kliewer SA; Gonzalez FJ
J Lipid Res; 2007 Dec; 48(12):2664-72. PubMed ID: 17720959
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.
Mueller M; Thorell A; Claudel T; Jha P; Koefeler H; Lackner C; Hoesel B; Fauler G; Stojakovic T; Einarsson C; Marschall HU; Trauner M
J Hepatol; 2015 Jun; 62(6):1398-404. PubMed ID: 25617503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
